Casdin Capital’s Guardant Health GH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$33M Hold
185,000
– – 1.44% 15
2026
Q2
$27.8M Sell
185,000
-130,000
-41% -$14.1M 1.39% 15
2026
Q1
$29.1M Sell
315,000
-65,000
-17% -$6.53M 2.2% 11
2025
Q4
$38.8M Buy
380,000
+280,000
+280% +$25M 2.41% 10
2025
Q3
$6.25M Hold
100,000
– – 0.52% 22
2025
Q2
$5.2M Sell
100,000
-150,000
-60% -$6.7M 0.47% 22
2025
Q1
$10.6M Sell
250,000
-100,000
-29% -$4.31M 0.87% 20
2024
Q4
$10.7M Hold
350,000
– – 0.71% 21
2024
Q3
$8.03M Buy
350,000
+250,000
+250% +$7.08M 0.54% 25
2024
Q2
$2.89M Buy
+100,000
New +$2.33M 0.22% 30
2022
Q3
– Sell
-272,500
Closed -$11M – 40
2022
Q2
$11M Sell
272,500
-147,500
-35% -$7.31M 0.93% 23
2022
Q1
$27.8M Sell
420,000
-370,000
-47% -$25.3M 1.25% 26
2021
Q4
$79M Buy
+790,000
New +$81.7M 2.23% 15

Other funds holding GH

Casdin Capital's GH Position: Q3 2026 in Review

Casdin Capital held its Guardant Health (GH) position steady in Q3 2026 at 185,000 shares worth $33M. The position accounts for 1.44% of the portfolio, ranked #15.

Casdin Capital first reported a position in GH in Q4 2021 and has held it in 13 quarters since. The position peaked at $79M in Q4 2021. 666 funds tracked by Wall St. Rank hold GH as of Q3 2026.

  • Casdin Capital held 185,000 shares of Guardant Health worth $33M as of Q3 2026.
  • Casdin Capital left its Guardant Health share count unchanged in Q3 2026.
  • Guardant Health made up 1.44% of Casdin Capital's portfolio in Q3 2026, its #15 holding.
  • Casdin Capital first reported a position in Guardant Health in Q4 2021 and has held it in 13 quarters since.
  • Casdin Capital's Guardant Health position peaked at $79M in Q4 2021.
  • 666 funds tracked by Wall St. Rank held Guardant Health as of Q3 2026.

Based on Casdin Capital's 13F filing for Q3 2026, filed 16 Nov 2026.